This study will take the patients white blood cells - T cells - and change them to turn against the cancer.

The Philadelphia Coalition for a Cure (PC4C) study is interested in collecting blood and saliva samples from you, as well as leftover tissue and cerebrospinal fluid from surgeries at CHOP.

Phase 1 open-label study to estimate the safety, manufacturing feasibility, and efficacy of intravenously administered, lentivirally transduced T cells expressing anti-CD123 in pediatric subjects with relapsed/refractory Acute Myeloid Leukemia.

This pilot study will assess these outcomes in children and young adults with PHTS ages 1 to 20 years.

CHOP, in collaboration with Dana-Farber Cancer Institute, is conducting a study for children, adolescents, and young adults up to 31 years old, with relapsed or refractory acute lymphoblastic leukemia. This clinical trial is adding the study drugs ribociclib and everolimus to a standard relapse chemotherapy regimen.

The purpose of this study is to determine the safety and tolerability of an experimental form of therapy, known as UCART22 ("study drug").